Nizatidine: Difference between revisions
m →History and development: Fix ugly typo |
Custardninja (talk | contribs) m Disambiguate Over the counter to Over-the-counter drug using popups |
||
Line 26: | Line 26: | ||
''Main article: [[H2-receptor antagonist]]'' |
''Main article: [[H2-receptor antagonist]]'' |
||
Certain preparations of nizatadine are now available [[over the counter]] in various countries including the United States. |
Certain preparations of nizatadine are now available [[Over-the-counter drug|over the counter]] in various countries including the United States. |
||
==History and development== |
==History and development== |
Revision as of 14:00, 2 June 2007
File:Nizatidine.png | |
Clinical data | |
---|---|
License data |
|
Pregnancy category |
|
Routes of administration | Oral |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | >70% |
Protein binding | 35% |
Metabolism | Hepatic |
Elimination half-life | 1-2 hours |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.155.683 |
Chemical and physical data | |
Formula | C12H21N5O2S2 |
Molar mass | 331.46 g/mol g·mol−1 |
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.
Clinical use
Main article: H2-receptor antagonist
Certain preparations of nizatadine are now available over the counter in various countries including the United States.
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine.
Nizatidine proved to be the last new histamine H2-receptor antagonists introduced prior to the advent of proton pump inhibitors.